MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kamboj, R. K.
Right arrow Articles by Wosnick, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamboj, R. K.
Right arrow Articles by Wosnick, M. A.

Molecular structure and pharmacological characterization of humEAA2, a novel human kainate receptor subunit

RK Kamboj, DD Schoepp, S Nutt, L Shekter, B Korczak, RA True, DM Zimmerman and MA Wosnick

Allelix Biopharmaceuticals Inc., Mississauga, Ontario, Canada.

A cDNA encoding a novel human glutamate receptor subunit protein was isolated from a human hippocampal library. This cDNA, termed humEAA2, is most closely related to rat cDNAs for kainate receptor proteins and, when expressed in COS cells, is associated with high affinity kainate receptor binding. The relative potency of compounds in displacing [3H]kainate binding was kainate greater than quisqualate greater than domoate greater than L-glutamate much greater than 6,7- dinitroquinoxaline-2,3-dione greater than dihydrokainate greater than 6- cyano-7-nitroquinoxaline-2,3-dione greater than (RS)-alpha-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid. Homomeric expression of humEAA2 does not appear to elicit ligand-gated channel activity. Nevertheless, the molecular structure and pharmacology of high affinity kainate binding suggest that humEAA2 is a novel subunit protein of a human kainate receptor complex.

Volume 42, Issue 1, pp. 10-15, 07/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Hald, P. Naur, D. S. Pickering, D. Sprogoe, U. Madsen, D. B. Timmermann, P. K. Ahring, T. Liljefors, A. Schousboe, J. Egebjerg, et al.
Partial Agonism and Antagonism of the Ionotropic Glutamate Receptor iGLuR5: STRUCTURES OF THE LIGAND-BINDING CORE IN COMPLEX WITH DOMOIC ACID AND 2-AMINO-3-[5-tert-BUTYL-3-(PHOSPHONOMETHOXY)-4-ISOXAZOLYL]PROPIONIC ACID
J. Biol. Chem., August 31, 2007; 282(35): 25726 - 25736.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
G. C. Mathews and J. S. Diamond
Neuronal Glutamate Uptake Contributes to GABA Synthesis and Inhibitory Synaptic Strength
J. Neurosci., March 15, 2003; 23(6): 2040 - 2048.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Poulopoulou and L. M. Nowak
Extracellular 3',5' Cyclic Guanosine Monophosphate Inhibits Kainate-Activated Responses in Cultured Mouse Cerebellar Neurons
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 99 - 109.
[Abstract] [Full Text]

Home page
 NeuroscientistHome page
R. G. Kalb
Current Excitement about the Glutamate Receptor Family
Neuroscientist, March 1, 1995; 1(2): 60 - 63.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1992 by the American Society for Pharmacology and Experimental Therapeutics